RealSeq Biosciences’ core expertise includes innovative proprietary technologies for bias-free small RNA/miRNA NGS library construction.
RealSeq Biosciences has raised $2.0M in total funding. The most recent round was Grant. The last funding was announced in September 2025.
RealSeq Biosciences's investors include National Institutes of Health, TCA Venture Group, Angel Star Ventures, MEDA Angels, Chemical Angel Network.
RealSeq Biosciences is headquartered in Santa Cruz, United States.
RealSeq Biosciences’ core expertise includes innovative proprietary technologies for bias-free small RNA/miRNA NGS library construction.
RealSeq Biosciences is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"RealSeq Biosciences — Funding & Investors." VCBacked, September 17, 2025, https://www.vcbacked.co/company/realseq-biosciences. Accessed July 19, 2026.
VCBacked. (2025). RealSeq Biosciences — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/realseq-biosciences
{{cite web |title=RealSeq Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/realseq-biosciences |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated